[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2970202T3 - Pochodne pirydynylu i połączonego pirydynylotriazolonu - Google Patents

Pochodne pirydynylu i połączonego pirydynylotriazolonu

Info

Publication number
PL2970202T3
PL2970202T3 PL14719130T PL14719130T PL2970202T3 PL 2970202 T3 PL2970202 T3 PL 2970202T3 PL 14719130 T PL14719130 T PL 14719130T PL 14719130 T PL14719130 T PL 14719130T PL 2970202 T3 PL2970202 T3 PL 2970202T3
Authority
PL
Poland
Prior art keywords
pyridinyl
fused
triazolone derivatives
derivatives
triazolone
Prior art date
Application number
PL14719130T
Other languages
English (en)
Inventor
John David Lawson
Mark Sabat
Nicholas Scorah
Christopher Smith
Phong H. Vu
Haixia Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL2970202T3 publication Critical patent/PL2970202T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL14719130T 2013-03-11 2014-03-10 Pochodne pirydynylu i połączonego pirydynylotriazolonu PL2970202T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11

Publications (1)

Publication Number Publication Date
PL2970202T3 true PL2970202T3 (pl) 2017-08-31

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14719130T PL2970202T3 (pl) 2013-03-11 2014-03-10 Pochodne pirydynylu i połączonego pirydynylotriazolonu

Country Status (42)

Country Link
US (4) US9402841B2 (pl)
EP (2) EP3235814B1 (pl)
JP (2) JP6271700B2 (pl)
KR (1) KR102300612B1 (pl)
CN (1) CN105121427B (pl)
AP (1) AP2015008646A0 (pl)
AR (1) AR095198A1 (pl)
AU (1) AU2014249248B2 (pl)
BR (1) BR112015020264B1 (pl)
CA (1) CA2899948C (pl)
CL (1) CL2015002370A1 (pl)
CR (1) CR20150470A (pl)
CY (1) CY1119356T1 (pl)
DK (1) DK2970202T3 (pl)
DO (1) DOP2015000184A (pl)
EA (1) EA028584B1 (pl)
EC (1) ECSP15042779A (pl)
ES (2) ES2624439T3 (pl)
GE (1) GEP201706778B (pl)
HK (2) HK1220183A1 (pl)
HR (1) HRP20170622T1 (pl)
HU (1) HUE032720T2 (pl)
IL (1) IL240353B (pl)
JO (1) JO3377B1 (pl)
LT (1) LT2970202T (pl)
MA (1) MA38391B1 (pl)
ME (1) ME02693B (pl)
MX (1) MX364527B (pl)
MY (1) MY183927A (pl)
PE (1) PE20151889A1 (pl)
PH (1) PH12015502046B1 (pl)
PL (1) PL2970202T3 (pl)
PT (1) PT2970202T (pl)
RS (1) RS55879B1 (pl)
SG (1) SG11201506112QA (pl)
SI (1) SI2970202T1 (pl)
TN (1) TN2015000342A1 (pl)
TW (1) TWI637950B (pl)
UA (1) UA114944C2 (pl)
UY (1) UY35376A (pl)
WO (1) WO2014164558A1 (pl)
ZA (1) ZA201505996B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3181567T (pt) 2012-09-10 2019-06-24 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
SG11201606858RA (en) 2014-02-21 2016-09-29 Principia Biopharma Inc Salts and solid form of a btk inhibitor
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
WO2016100914A1 (en) * 2014-12-18 2016-06-23 Gourlay Steven Treatment of pemphigus
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3394045B1 (en) * 2015-12-24 2021-05-19 Takeda Pharmaceutical Company Limited Cocrystal, production method thereof, and medicament containing cocrystal
DK3402503T3 (da) * 2016-01-13 2020-12-21 Acerta Pharma Bv Terapeutiske kombinationer af et antifolat og en btk-hæmmer
JP7305352B2 (ja) * 2016-03-31 2023-07-10 武田薬品工業株式会社 イソキノリニルトリアゾロン錯体
CN109600989B (zh) 2016-06-29 2022-11-04 普林斯匹亚生物制药公司 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
US20210308140A1 (en) 2018-07-25 2021-10-07 Novartis Ag Nlrp3 inflammasome inhibitors
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020253853A1 (en) * 2019-04-02 2021-11-11 Yonsei University, University - Industry Foundation (UIF) Novel compound and method for preventing or treating of respiratory disease comprising the same as an active ingredient
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP7545570B2 (ja) 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002512216A (ja) 1998-04-17 2002-04-23 パーカー ヒューズ インスティテュート Btkインヒビターならびにその同定方法および使用方法
JP2004509115A (ja) * 2000-09-15 2004-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
ES2484042T3 (es) * 2006-05-25 2014-08-08 Synta Pharmaceuticals Corporation Compuestos de triazol que modulan la actividad de HSP90
BRPI0713736A2 (pt) 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
LT2529622T (lt) 2006-09-22 2018-05-10 Pharmacyclics Llc Brutono tirozinkinazės inhibitoriai
CA3143428A1 (en) 2007-03-28 2008-10-09 Pharmacyclics Llc 8-amino-3-substituted-imidazo[1,5-a]pyrazine and use thereof as inhibitors of bruton's tyrosine kinase
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
MX2010008197A (es) 2008-02-05 2010-08-23 Hoffmann La Roche Nuevas piridinonas y piridazinonas.
BRPI0914657A2 (pt) 2008-06-24 2019-09-24 F Hoffmann La Roche piridin-2-onae piridazin-3-onas substituídas
RU2507202C2 (ru) 2008-07-02 2014-02-20 Ф.Хоффманн-Ля Рош Аг Новые фенилпиразиноны в качестве ингибиторов киназы
WO2010006947A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
AU2011253003B2 (en) 2010-05-13 2014-05-01 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
KR101820645B1 (ko) 2010-10-20 2018-01-22 그뤼넨탈 게엠베하 Kcnq2/3 조절제로서의 치환된 6­아미노­니코틴아미드
WO2012064972A2 (en) 2010-11-10 2012-05-18 Stc.Unm Aerosol reduction/expansion synthesis (a-res) for zero valent metal particles
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
CL2015002370A1 (es) 2016-03-11
PE20151889A1 (es) 2015-12-26
JP2016512515A (ja) 2016-04-28
MA38391A1 (fr) 2018-01-31
BR112015020264B1 (pt) 2021-03-02
AP2015008646A0 (en) 2015-08-31
MX2015011533A (es) 2016-02-03
CA2899948C (en) 2021-11-16
SI2970202T1 (sl) 2017-07-31
HK1245256B (zh) 2019-09-27
BR112015020264A2 (pt) 2017-07-18
MX364527B (es) 2019-04-30
NZ710852A (en) 2020-12-18
EP3235814A1 (en) 2017-10-25
UA114944C2 (uk) 2017-08-28
US20140256734A1 (en) 2014-09-11
CY1119356T1 (el) 2018-02-14
IL240353A0 (en) 2015-09-24
TN2015000342A1 (en) 2017-01-03
EP3235814B1 (en) 2018-12-12
CN105121427A (zh) 2015-12-02
HRP20170622T1 (hr) 2017-06-30
EA028584B1 (ru) 2017-12-29
US9402841B2 (en) 2016-08-02
PH12015502046A1 (en) 2016-01-18
ZA201505996B (en) 2016-11-30
CR20150470A (es) 2016-01-11
KR20150126687A (ko) 2015-11-12
HK1220183A1 (zh) 2017-04-28
US20160310483A1 (en) 2016-10-27
US20190224190A1 (en) 2019-07-25
ECSP15042779A (es) 2017-08-31
US9801872B2 (en) 2017-10-31
RS55879B1 (sr) 2017-08-31
JP2018076357A (ja) 2018-05-17
HUE032720T2 (en) 2017-10-30
KR102300612B1 (ko) 2021-09-09
TWI637950B (zh) 2018-10-11
DOP2015000184A (es) 2015-11-30
EA201591686A1 (ru) 2015-12-30
US20180015083A1 (en) 2018-01-18
ES2714166T3 (es) 2019-05-27
ME02693B (me) 2017-10-20
ES2624439T3 (es) 2017-07-14
CN105121427B (zh) 2018-04-10
UY35376A (es) 2014-10-31
JO3377B1 (ar) 2019-03-13
EP2970202B1 (en) 2017-02-01
MY183927A (en) 2021-03-17
LT2970202T (lt) 2017-06-12
TW201522328A (zh) 2015-06-16
GEP201706778B (en) 2017-11-27
DK2970202T3 (en) 2017-05-08
PH12015502046B1 (en) 2016-01-18
AU2014249248A1 (en) 2015-08-20
US10307414B2 (en) 2019-06-04
EP2970202A1 (en) 2016-01-20
SG11201506112QA (en) 2015-09-29
JP6462842B2 (ja) 2019-01-30
IL240353B (en) 2018-11-29
CA2899948A1 (en) 2014-10-09
AU2014249248B2 (en) 2017-08-17
AR095198A1 (es) 2015-09-30
PT2970202T (pt) 2017-05-03
JP6271700B2 (ja) 2018-01-31
MA38391B1 (fr) 2018-09-28
WO2014164558A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
HK1245256B (zh) 吡啶基和稠合吡啶基三唑酮衍生物
HK1219658A1 (zh) 吡咯並苯並二氮雜卓及其結合物
HK1219651A1 (zh) 吡咯並苯並二氮雜卓以及其結合物
HK1214140A1 (zh) 吡咯並苯並二氮雜卓和其結合物
HK1218512A1 (zh) 雜環化合物和其用途
HUE038595T2 (hu) Dohányzacskó
EP3004057A4 (en) HETEROCYCLIC DERIVATIVES AND THEIR USE
ZA201507657B (en) Pyridin-4-yl derivatives
IL244383A0 (en) Triazolone compounds and their uses
HK1220363A1 (zh) 雜環化合物及其用途
IL245597B (en) Anti-neuroinflammatory and protective compounds in Achillea fragrantissima - implications for inflammatory and neurodegenerative diseases
EP2970138A4 (en) PYRAZONE DERIVATIVES AND USES THEREOF
GB201304115D0 (en) Fusion ploypeptide
GB201301120D0 (en) Improvements in joint forming devices